Agile therapeutics inc (AGRX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating expenses:
Research and development

9,858

9,777

14,428

20,929

25,622

13,365

9,154

17,386

General and administrative

9,000

8,739

12,383

8,792

7,467

5,150

3,574

5,929

Charges

0

1,019

-

-

-

-

-

-

Total operating expenses

18,858

19,535

26,811

29,721

33,089

18,515

12,728

23,316

Loss from operations

-18,858

-19,535

-26,811

-29,721

-33,089

-18,515

-12,728

-23,316

Other income (expense)
Interest income

252

366

282

117

5

3

1

25

Interest expense

-

1,116

1,918

2,446

2,077

1,566

1,513

140

Change in fair value of warrants

-

29

143

-

-

-

-

-

Change in fair value of warrants

-

-

-

-234

110

-348

81

-171

Loss on extinguishment of debt

-

-

-

-

-1,036

-

-

-

Total other income (expense), net

252

-721

-1,493

-2,095

-3,218

-

-

-

Loss before benefit from income taxes

-18,606

-20,256

-28,304

-31,816

-36,307

-19,730

-14,321

-

Loss before benefit from income taxes

-

-

-

-

-

-

-

-23,260

Benefit from income taxes

-

-477

-

-3,075

-5,972

-3,653

-

-

Net loss

-18,606

-19,779

-28,304

-28,741

-30,335

-

-

-23,260

Beneficial conversion charge

-

-

-

-

-

-

-

600

Net loss

-

-

-

-

-

-16,077

-14,321

-23,860

Net loss per share (basic and diluted) (in dollars per share)

-0.38

-0.58

-0.91

-1.02

-1.38

-1.41

-289.39

-603.78

Weighted-average common shares (basic and diluted) (in shares)

49,432

34,315

30,940

28,273

22,017

11,394

49

39